Zura Bio (ZURA) Projected to Post Quarterly Earnings on Thursday

Zura Bio (NASDAQ:ZURA) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter.

Zura Bio Stock Performance

NASDAQ:ZURA opened at $1.42 on Thursday. Zura Bio has a 12-month low of $1.07 and a 12-month high of $6.35. The business has a 50 day simple moving average of $1.54 and a 200 day simple moving average of $2.84.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Zura Bio stock. Bank of America Corp DE grew its holdings in shares of Zura Bio Limited (NASDAQ:ZURA) by 31.9% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 41,222 shares of the company’s stock after acquiring an additional 9,966 shares during the quarter. Bank of America Corp DE owned about 0.06% of Zura Bio worth $103,000 as of its most recent SEC filing. 61.14% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ZURA has been the subject of a number of analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research report on Wednesday, December 11th. HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Zura Bio in a research report on Tuesday, December 24th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $15.80.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.